SCHEMBL10242579

SCHEMBL10242579

O=C(Nc1ccc(F)cc1)C1CCC1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.69
PTPN1 P18031 2/20 0.66
RAB9A P51151 3/20 0.65
NPC1 O15118 1/20 0.65
ENPP3 O14638 3/20 0.63
ENPP1 P22413 2/20 0.63
ENPP2 Q13822 2/20 0.63
LMNA P02545 3/20 0.61
MEN1 O00255 1/20 0.61
HPGD P15428 1/20 0.61
POLB P06746 1/20 0.59
NAMPT P43490 1/20 0.58
TSHR P16473 1/20 0.57
MAPT P10636 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HTT P42858 1/20 0.56
CCNA2 P20248 1/20 0.56
CDK2 P24941 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42558 0.96 PTPN1 (0.71) KMT2APTPN1RAB9ANPC1ENPP3
SCHEMBL8296637 0.95 PTPN1 (0.74) KMT2APTPN1RAB9ANPC1ENPP3
SCHEMBL14734057 0.92 KMT2A (0.78) KMT2APTPN1RAB9ANPC1ENPP3
Hydrochloric Acid SCHEMBL5794594 0.91 KMT2A (0.76) KMT2APTPN1RAB9ANPC1ENPP3
SCHEMBL27840833 0.87 KMT2A (0.71) KMT2APTPN1RAB9ANPC1ENPP3
Formamide SCHEMBL18488991 0.84 KMT2A (0.68) KMT2APTPN1RAB9ANPC1ENPP3
SCHEMBL4677815 0.84 KMT2A (0.63) KMT2APTPN1RAB9ANPC1ENPP3
SCHEMBL4677821 0.84 KMT2A (0.63) KMT2APTPN1RAB9ANPC1ENPP3
SCHEMBL28656982 0.84 PTPN1 (0.89) KMT2APTPN1RAB9ANPC1ENPP3
SCHEMBL125695 0.84 PTPN1 (0.89) KMT2APTPN1RAB9ANPC1ENPP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111344287-B Novel substituted biaryl compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors 默沙东有限责任公司 2023-12-19 CN disclosed
US-20190241533-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2019-08-08 US disclosed
WO-2013028670-A1 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2013-02-28 WO disclosed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241533-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD KMT2A 4741/4885PTPN1 4255/4885RAB9A 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.